Tong Ren Tang Chinese Medicine Company Limited at its extraordinary general meeting of the Company to be convened to, among other things, consider and, if thought fit, approve the New Exclusive Distributorship Framework Agreements and the proposed annual caps contemplated thereunder, "Existing Exclusive Distributorship Framework Agreements, collectively, the Existing TRT Tech Exclusive Distributorship Framework Agreement and the Existing TRT Ltd. Exclusive Distributorship Framework Agreement, "Existing TRT Ltd. Exclusive distribution framework agreement dated 6 November 2020 entered into between the Company and Tong Ren Tang Ltd. in relation to the distribution of the Relevant Products of the Tong Ren Tang Ltd. Group in markets outside the Mainland China, "Group", the Company and its subsidiaries (either directly owned or indirectly owned), "HK$, Hong Kong dollar, the lawful currency of Hong Kong, "Hong Kong Special Administrative Region of the PRC, "Independent Board Committee", the independent board committee of the Company comprising all the independent non-executive Directors, namely Mr. Tsang Yok Sing, Jasper, Mr. Xu Hong Xi and Mr. Chan Ngai Chi, formed for the purpose of advising the Independent Shareholders in respect of the terms of the New Exclusive Distributorship Framework Agreement (including the proposed annual caps), "Independent Shareholders, Shareholders other than the Parent Group, "Listing Rules", The Rules Governing the Listing of Securities on the Stock Exchange (as amended from time to time), "Mainland China", the PRC and for the purpose of this announcement, excluding Hong Kong, the Macao Special Administrative Region of the PR C and Taiwan region, "New Exclusive Distributorship Framework Agreements", collectively, the New TRT Tech Exclusive Distributorship framework agreement, "New TRT Ltd., Exclusive, Distributorship, Framework Agreement, the new exclusive distributorship framework agreement dated 29 November 2023 entered into between the Company andong Ren Tang Technologies in relation to the distribution of The Relevant Products of the TongRen Tang Technologies Group in markets outside the Main land China, "Parent Group", Tong Ren Tang Holdings, Tong Ren Tang Ltd., Tong Ren Tang Ltd., TongRen Tang Technologies and their respective associates (excluding the Group), "PRC", the People's Republic of China, "Relevant Products", the "Tong Ren Tang" branded products and/or Chinese medicine products supplied by the Tong Ren Tang Ltd. group or the Tong Ren Tang Technologies Group to TRT International Natural-Pharm under the New Exclusive Distributorship Framework agreements for the purpose of the distribution or production in the markets outside the Mainland China.